Lansdale, PA, United States of America

Stuart R Michelson

This inventor holds 2 USPTO granted patents. Top assignee: Merck + Co., Inc.. Active years: 1983-1984.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 40(Granted Patents)


Company Filing History:


Years Active: 1983-1984

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Stuart R Michelson

Introduction

Stuart R Michelson is a notable inventor based in Lansdale, PA (US). He has made significant contributions to the field of ophthalmology through his innovative patents. With a total of 2 patents, Michelson's work focuses on treatments for elevated intraocular pressure.

Latest Patents

Michelson's latest patents include the following:

1. **5-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure**. This invention involves ophthalmic compositions, including drops and inserts, that are designed to effectively manage this condition.

2. **6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure**. Similar to his previous patent, this invention also focuses on ophthalmic compositions that aid in the treatment of elevated intraocular pressure.

Career Highlights

Stuart R Michelson is currently associated with Merck & Co., Inc., a leading pharmaceutical company. His work at Merck has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Throughout his career, Michelson has collaborated with esteemed colleagues, including Otto W Woltersdorf, Jr and John M Sondey. These collaborations have fostered a creative environment that encourages the development of groundbreaking solutions in ophthalmology.

Conclusion

Stuart R Michelson's contributions to the field of ophthalmology through his patents demonstrate his commitment to innovation and improving patient care. His work continues to influence the development of effective treatments for elevated intraocular pressure.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…